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Abstract
Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall
response (OR) rates, complete response (CR) rates and progression free survival (PFS). Despite
these advances, CLL remains incurable with standard therapies. Thus, there remains a need for
more effective therapies in both the upfront and relapsed setting, particularly for patients with high-
risk cytogenetic abnormalities such as del(11q22) and del(17p13). The 2008 American Society of
Hematology (ASH) Annual Meeting featured several presentations which highlighted the ongoing
clinical advances in CLL. The benefit of adding rituximab to purine analog therapy in the upfront
setting was demonstrated by a large randomized study which showed that the addition of rituximab
to fludarabine and cyclophosphamide (FCR) significantly improved OR, CR and PFS. The
improvement in PFS directly resulted from an improved ability to eliminate minimal residual disease
(MRD) in the peripheral blood, highlighting the importance of MRD eradication. However, a multi-
center study suggested that the high CR rates to chemoimmunotherapy regimens such as FCR
obtained in academic centers may not be reproducible when the same regimens are given in the
community setting. The immunomodulatory drug lenalidomide is active in relapsed high-risk CLL,
but two studies of lenalidomide in previously untreated CLL patients failed to achieve a CR and
were associated with significant tumor lysis, tumor flare and hematologic toxicity. In the relapsed
setting, a combination study of the bifunctional alkylator bendamustine and rituximab (BR)
demonstrated a high OR rate in patients with del(11q22) and del(17p13), indicating that further
studies to define's bendamustine activity are warranted in high-risk CLL. Similarly, the CDK
inhibitor flavopiridol demonstrated significant clinical activity and durable remissions in heavily
treated, refractory CLL patients with high-risk cytogenetic features and bulky lymphadenopathy.
The monoclonal anti-CD20 antibody ofatumumab appeared to be superior to rituximab in relapsed
CLL patients with bulky nodal disease or high-risk cytogenetic features. Ongoing studies of these
agents and other novel therapeutic agents in clinical development hold forth the promise that
treatment options for CLL patients will continue to expand and improve.
Introduction
Chronic lymphocytic leukemia (CLL) is the most com-
mon adult leukemia in the Western hemisphere.
Although patients with early stage disease have a greater
than 10 year life expectancy, patients with more advanced
disease have a median survival of 18 months to 3 years
and those who have fludarabine refractory disease have a
median survival of less than one year. Advances in the
therapy for CLL, particularly "chemoimmunotherapy"
regimens combining cytotoxic agents such as alkylating
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agents and purine nucleoside analogs with monoclonal
antibodies such as rituximab, have improved initial over-
all response (OR) rates, complete response (CR) rates and
progression free survival (PFS). Despite these advances,
CLL remains incurable with standard therapies; patients
inevitably relapse, become increasingly refractory to treat-
ment, and often acquire high-risk chromosomal abnor-
malities such as del(11q22) and del(17p13), which
correspond to loss of the ataxia telangiectasia mutated
(ATM) and p53 tumor suppressor genes, respectively.
Thus, there remains a need for more effective therapies in
both the upfront and relapsed setting. This review high-
lights advances in the treatment of CLL in both previously
untreated and relapsed disease and focuses on new data
presented at the 2008 American Society of Hematology
(ASH) Annual Meeting.
Background studies
Indications for therapy
The 1996 NCI Working Group established guidelines for
initiating treatment for CLL, which were affirmed in 2008
by the International Workshop on CLL[1,2]. Indications
include autoimmue and non-autoimmune cytopenias,
bulky or symptomatic lymphadenopathy or organomeg-
aly, disease-related B-symptoms or fatigue, and rapid lym-
phocyte doubling time. Since CLL is typically diagnosed
by routine complete blood count examination, most
patients are asymptomatic without cytopenias at diagno-
sis. Asymptomatic patients should be followed expect-
antly and should receive treatment only upon disease
progression. While ongoing, prospective studies such as
the Cancer and Leukemia Group B (CALGB) 10501 trial
are studying whether early intervention affects long-term
outcome of patients with high-risk features such as unmu-
tated IgVH, there currently are no data supporting early
therapy for high-risk CLL patients who do not meet crite-
ria for therapy. Any early treatment intervention for
asymptomatic high-risk patients should only be per-
formed in the setting of a clinical study. Thus, it is impor-
tant to determine that all patients required therapy by NCI
and IWCLL criteria when evaluating results of upfront
clinical studies in CLL. Of note, many studies in previ-
ously untreated CLL focus on the CR rate and PFS,
whereas overall survival (OS) remains the most meaning-
ful endpoint of any therapeutic cancer trial. Nonetheless,
CR and PFS are important measures of a treatment's effi-
cacy, as patients who achieve CR and enjoy prolonged PFS
are likely to experience improved quality of life. Further-
more, identification of regimens which achieve high CR
rates and durable PFS will provide insight for investigators
to develop more effective future treatment strategies.
Fludarabine combined with alkylator therapy
Three large, prospective, randomized, multi-center studies
showed that combination therapy with fludarabine and
cyclophosphamide (FC) is superior to fludarabine alone
with respect to OR, CR, and PFS in previously untreated
CLL patients (Table 1). However, there was no benefit in
OS in any of these studies. The German CLL Study Group
(GCLLSG) randomized 375 patients to fludarabine 25
mg/m2 intravenously (IV) daily for 5 days versus fludara-
bine 30 mg/m2 IV and cyclophosphamide 250 mg/m2 IV
daily for 3 days every 28 days for 6 cycles [3]. This study
showed improved OR (94% vs. 83%), CR (24% vs. 7%),
and PFS (48 vs. 20 months) in favor of FC. ECOG rand-
omized 278 patients to fludarabine 25 mg/m2 IV daily for
5 days versus fludarabine 20 mg/m2 IV daily for 5 days
and cyclophosphamide 600 mg/m2 IV day 1 every 28 days
Table 1: Selected Trials in Previously Untreated CLL Patients
Reference Regimen Phase No. Pts. CR, % ORR, % Median PFS (months)
Eichhorst, 2006 Flu III 164 7 83 20
Flu + Cy 164 24 94 48
Flinn, 2007 Flu III 137 5 59 19
Flu + Cy 141 23 74 32
Catovsky, 2007 Chl III 387 7 72 Not Rep
Flu 194 15 80 Not Rep
Flu + Cy 196 38 94 Not Rep
Byrd, 2003 FR (C) Rand. II 51 47 90 NR
FR (S) 53 28 77 NR
Keating, 2005 FCR II 300 72 94 NR
Hallek, 2008 FC III 409 23 85 32
FCR 408 45 93 43
Kay, 2007 PCR II 64 41 91 31
Kay, 2008 PR II 33 30 79 12
Reynolds, 2008 PCR III 92 7 45 Not Rep
FCR 92 17 58 Not Rep
Key: No-Number; Flu-fludarabine; CLB-Chlorambucil; Cy-cyclophosphamide; Ritux-rituximab; FR (C) – fludarabine + rituximab, concurrent; FR (S) 
– fludarabine + rituximab, sequential; FCR – fludarabine, cyclophosphamide, rituximab; PCR – pentostatin, cyclophosphamide, rituximab; PR – 
pentostatin + rituximab; CR – complete response rate; ORR – overall response rate; PFS – progression free survival; NR – not reached; Not Rep – 
Not reportedJournal of Hematology & Oncology 2009, 2:29 http://www.jhoonline.org/content/2/1/29
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for 6 cycles [4]. Results favored FC with respect to OR
(74% vs. 59%), CR (23% vs. 5%), and PFS (32 vs. 19
months). Lastly, the United Kingdom CLL4 study rand-
omized 777 patients to oral chlorambucil, fludarabine, or
FC [5]. Again, patients receiving FC achieved superior OR
(94% vs. 80%), CR (38% vs. 15%), and 5-year PFS (36%
vs. 10%). Importantly, the study showed that patients
with del(11q22) fared better with FC, but that patients
with del(17p13) did poorly regardless of the treatment
arm.
Chemoimmunotherapy
The addition of the monoclonal anti-CD20 antibody
rituximab to purine analog based therapy also increased
OR, CR and PFS without benefit in OS, as summarized in
Table 1. The CALGB 9712 study randomized 104 patients
to fludarabine with sequential or concurrent rituximab
[6]. Patients received fludarabine 25 mg/m2 days 1–5
every 28 days for 6 cycles with or without rituximab 375
mg/m2 on day 1 of cycles 1–6 and day 4 of cycle 1. All
patients received rituximab 375 mg/m2 weekly for 4 doses
beginning 2 months after completion of fludarabine.
Patients in the concurrent FR arm had superior OR (90%
vs. 77%) and CR (47% vs. 28%), but there was no differ-
ence in PFS between the two arms. The MD Anderson
Cancer Center (MDACC) demonstrated superior results
with the combination of fludarabine, cyclophosphamide
and rituximab (FCR). The MDACC treated 300 patients
with fludarabine 25 mg/m2 and cyclophosphamide 250
mg/m2 on days 2–4 of cycle 1 and days 1–3 of cycles 2–6,
and rituximab 375 mg/m2 on day 1 of cycle 1 and 500 mg/
m2 on day 1 of cycle 2–6, every 28 days for 6. OR was 94%,
CR was 72%, 4-year relapse free survival (RFS) was 77%,
and 4-year OS was 83% [7]. The impact of poor risk
cytogenetic factors on response to FCR was not reported.
While FR and FCR achieved excellent results, the median
age of patients in these studies was 63 and 58 years,
respectively, in contrast to a median age of 72 at first ther-
apy in the SEER database. A phase II study of PCR in 64
previously untreated CLL patients, including 18 ≥ age 70
years, indicated that older patients tolerate and respond to
PCR [8,9]. Patients received pentostatin 2 mg/m2 on day
1, cyclophosphamide 600 mg/m2 on day 1, and rituximab
375 mg/m2 on day 1 (100 mg/m2 on day 1 and 375 mg/
m2 on day 3 and 5 of cycle 1) every 21 days for up to 6
cycles. PCR was well tolerated. OR was 91%, CR was 41%,
and median PFS was 33 months (Table 1). The ability to
achieve CR was independent of del(11q22), but all 3
patients with del(17p13) failed to achieve a CR.
New data presented at the 2008 ASH Annual 
Meeting
Chemoimmunotherapy
Based on the above background studies, it is clear that
adding cyclophosphamide to fludarabine in the upfront
setting improves OR, CR and PFS in CLL. Kay and col-
leagues recently examined whether the addition of an
alkylating agent to other purine nucleoside analogs simi-
larly improves outcomes [10]. The Mayo Clinic and Ohio
State retrospectively compared results of a phase II study
of pentostatin and rituximab (PR) to previously published
results using pentostatin, cyclophosphamide and rituxi-
mab (PCR) [8]. The pentostatin dose was increased to 4
mg/m2 in the PR regimen, but demographics of patients in
both studies were similar. OR and CR rates were similar
for PR (79%, 30%) and PCR (91%, 41%), but median PFS
was significantly shorter for PR (12 months) compared to
PCR (31 months). These results supported previous find-
ings, described above, that the addition of cyclophospha-
mide to fludarabine improves OR, CR and PFS (Table 1).
While excellent results were obtained with FR and FCR in
phase II studies, the benefit of adding rituximab to a
purine nucleoside analog has not been examined in a pro-
spective randomized trial. Therefore, the GCLLSG CLL8
study randomized 817 previously untreated patients to
fludarabine 25 mg/m2 days 1–3 and cyclophosphamide
250 mg/m2 days 1–3, with or without rituximab 500 mg/
m2 day 1 (375 mg/m2 day 1 of cycle 1) [11]. OR, CR and
median PFS favored FCR (93%, 45%, 43 months) over FC
(85%, 23%, 32 months), although 2-year OS (91% vs.
88%) was similar (Table 1). The MDACC FCR trial previ-
ously showed that the ability to achieve ≤ 1% residual CLL
by two-color flow cytometry significantly affected relapse
free survival (RFS) and OS [7]. Five of 138 patients (4%)
whose post-FCR bone marrow flow cytometry had ≤ 1%
residual CLL relapsed, in contrast to 17 of 62 patients
(27%) with > 1% residual CLL. The importance of eradi-
cating minimal residual disease (MRD) was confirmed by
the GCLLSG CLL8 trial, which demonstrated that median
PFS depended upon the ability to eradicate MRD in the
peripheral blood, with PFS increasing from 15 months
(MRD ≥ 10-2) to 34 months (10-4 ≥ MRD > 10-2) to not
reached (MRD < 10-4) with increasing eradication of MRD
[12]. Furthermore, 67% of patients receiving FCR
achieved MRD < 10-4, compared to only 34% of FC
patients, thus accounting for the improved PFS with FCR.
In addition to reaffirming the importance of eradicating
MRD, the GCLLSG CLL8 study demonstrated that MRD
can be determined from peripheral blood and that bone
marrow biopsies are not necessary to gain MRD informa-
tion.
While regimens such as FR, FCR and PCR have achieved
excellent results in academic centers, there are limited
data on whether such regimens are able to achieve similar
results in the community setting. Therefore, US Oncology
performed a multicenter, community-based trial that ran-
domized 184 patients (80% previously untreated, 20%
relapsed) to PCR or FCR, using the Memorial Sloan Ketter-
ing PCR regimen (pentostatin dose 4 mg/m2) given for 8Journal of Hematology & Oncology 2009, 2:29 http://www.jhoonline.org/content/2/1/29
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cycles and the Johns Hopkins FCR regimen (fludarabine
20 mg/m2 days 1–5, cyclophosphamide 600 mg/m2 day
1) [13]. The primary endpoint, incidence of grade 3–4
infections, was similar for PCR (34%) and FCR (31%).
Only 50% of patients in both arms completed therapy,
resulting in surprisingly low OR and CR rates for PCR
(45%, 7%) and FCR (58%, 17%), as summarized in Table
1. While the study was not powered to show a statistically
significant difference between FCR and PCR, these find-
ings indicated that results from academic centers may not
necessarily be reproducible in the community. Specifi-
cally, a reduced ability to complete planned treatment
may reduce the clinical efficacy of these regimens outside
academic centers.
Because of the ability of the anti-CD52 alemtuzumab
(Campath-1H) to eradicate MRD and its activity in high-
risk CLL patients, the MDACC added alemtuzumab to
FCR, to determine if the efficacy of FCR could be
improved [14]. The CFAR regimen consists of fludarabine
25 mg/m2 on days 2–4, cyclophosphamide 250 mg/m2 on
days 2–4, rituximab 375 mg/m2 (cycle 1) or 500 mg/m2
(cycles 2–6) on day 2, and alemtuzumab 30 mg IV on
days 1, 3 and 5 every 28 days for up to 6 cycles. Patients
receive pegfilgrastrim, as well as prophylaxis for pneumo-
cystis carinii pneumonia (PCP) and cytomegalovirus
(CMV). A phase II study in 78 relapsed CLL patients had
attained OR 65% (CR 24%); median PFS was 27 months
for the 19 CR patients and 10 months for the 32 PR
patients. Given these promising results, the MDACC is
conducting a phase II study of CFAR in previously
untreated patients [15]. Results in the first 48 patients
with high-risk features revealed OR and CR of 94% and
69%, respectively, with OR 77% and CR 54% in 13
patients with del(17p13). Grade 3–4 neutropenia and
thrombocytopenia were observed in 71% and 42% of
patients, respectively, and 6% and 27% of patients devel-
oped major and minor infections, respectively. While the
results do not appear to be superior to FCR at first glance,
it must be noted that CFAR is being tested in higher risk
patients and that PFS data are not yet available.
Novel agents
Bendamustine hydrochloride is a novel alkylating agent
which contains a benzimidazole ring and is only partially
cross-resistant with other alkylating agents in vitro. The
FDA approved bendamustine for the treatment of CLL in
2008 based upon a multi-center, European phase III study
which randomized 319 previously untreated CLL patients
to oral chlorambucil 0.8 mg/kg on day 1 and 15 every 28
days or bendamustine 100 mg/m2 IV on day 1 and 2 every
28 days [16]. Treatment in both arms was given for up to
6 cycles or until disease progression. The results of this
study were updated at the 2008 ASH meeting. OR, CR and
median PFS favored bendamustine (67%, 32%, 21.5
months) over chlorambucil (30%, 2%, 8.3 months),
although bendamustine caused greater hematologic toxic-
ity (40% vs. 19%), especially grade 3–4 neutropenia (23%
vs. 9%) [17]. The GLLSG is currently conducting a rand-
omized trial in previously untreated patients to compare
the combination of bendamustine and rituximab (BR) to
the MDACC regimen of FCR, which has achieved the
highest CR rate of any upfront CLL regimen to date.
Lenalidomide is an immunomodulatory drug that is a
more potent analog of thalidomide. Lenalidomide has
shown activity in relapsed CLL patients including activity
in patients with high-risk cytogenetic features. The
Roswell Park Cancer Insititute conducted a phase II study
which administered lenalidomide 25 mg daily orally on
days 1–21 every 28 days to 45 patients with relapsed CLL
[18]. Results showed OR and CR rates of 47% and 9%,
and responses were observed in fludarabine refractory
patients and those with poor-risk 11q22 and 17p13 dele-
tions. The MDACC chose a different dosing strategy and
administered lenalidomide by continuous low dose at 10
mg orally daily, with a 5 mg dose escalation every 28 days
up to a maximum dose of 25 mg daily, to 44 patients with
relapsed CLL with 10 mg being the median delivered dose
[19]. OR and CR rates of 32% and 7% were observed, and
the OR rate was 31% in patients with high-risk cytogenetic
abnormalities. However, tumor lysis and tumor flare reac-
tions are potentially serious toxicities of lenalidomide,
and the optimal dosing schedule with respect to safety
and efficacy are undefined.
Two studies of lenalidomide in previously untreated
patients were presented at the 2008 ASH meeting. Chen et
al. summarized results of a phase I study in 25 Canadian
patients [20]. Due to grade 5 sepsis and grade 3–4 tumor
lysis, the dose was decreased from 25 mg to 2.5 mg and
then escalated to 10 mg daily for 21 days every 28 days.
Toxicity included fatigue (78%), tumor flare (78%), rash
(48%) and grade 3–4 neutropenia (43%). OR and CR
were 65% and 0%, respectively. The MDACC presented a
study in 43 elderly patients age 65 years or older [19].
Lenalidomide was given continuously, and 5–10 mg daily
was the median delivered dose. Grade 3–4 myelosuppres-
sion and tumor flare were observed in 26% and 44% of
patients, respectively. OR and CR were 54% and 0%,
respectively. While lenalidomide is clearly active in CLL,
the absence of CR in previously untreated patients was
disappointing.
Finally, James et al. presented a phase II study giving high
dose methylprednisolone 1000 mg/m2 day 1–3 every four
weeks and weekly rituximab (total dose 4500–6750 mg/
m2) to 28 previously untreated patients [21]. OR and CR
were 96% and 32%, respectively. Patients with less prom-
inent splenomegaly and lower beta-2-microglobulin lev-
els were more likely to respond.Journal of Hematology & Oncology 2009, 2:29 http://www.jhoonline.org/content/2/1/29
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Relapsed CLL
Despite advances in first line therapy for CLL, patients
invariably relapse and often acquire high risk chromo-
somal abnormalities such as del(11q22) and del(17p13),
which result in resistance to therapy [22,23]. Patients who
have fludarabine refractory disease have a median survival
of less than one year. Thus, new agents are needed for the
treatment of relapsed CLL, particularly for those patients
with high-risk cytogenetic features. It is important to
emphasize that the same NCI and IWCLL criteria for initi-
ating therapy in previously untreated patients also apply
for patients with relapsed CLL [1,2]. Asymptomatic
relapsed patients should be followed expectantly and
should receive treatment only upon development of cyto-
penias or symptoms.
Stilgenbauer et al. presented final results of the GCLLSG
CLL2H study which administered subcutaneous alemtu-
zumab to 103 relapsed patients, many of whom had high-
risk features [24]. Infusion toxicity was minimal, but
grade 3–4 anemia (56%), thrombocytopenia (57%), ane-
mia (49%), cytomegalovirus reactivation (8%) and non-
CMV infection (29%) were significant toxicities. Seventy-
five patients died; 56% died of progressive CLL, and 31%
died of infection. OR (34%), CR (4%) and median PFS
(7.7 months) were similar to the results achieved by IV
alemtuzumab in the pivotal CAM211 study [25]. While
alemtuzumab was an effective therapy, the outcome for
high-risk patients remained poor without the use of allo-
geneic stem cell transplantation.
The GCLLSG presented a phase II trial administering ben-
damustine 70 mg/m2 on day 1–2 and rituximab 500 mg/
m2 on day 1 to 81 relapsed CLL patients [26]. OR and CR
were 77% and 15%, respectively. Twelve of 13 patients
(92%) with del(11q22), 4/9 patients (44%) with
del(17p13), and 29/39 patients (74%) with unmutated
IgVH responded, suggesting that bendamustine may be
active in high-risk relapsed CLL. However, further studies
are needed to determine whether bendamustine can be
considered as a treatment for relapsed CLL patients with
poor-risk features.
Flavopiridol is a synthetic flavone which broadly inhibits
cyclin dependent kinases (CDK); down-regulates expres-
sion of anti-apoptotic proteins such as Mcl-1 and X-linked
inactivator of apoptosis (XIAP); decreases phosphoryla-
tion and transcriptional activity of RNA polymerase II,
resulting in decreased gene transcription; and induces
apoptosis distally to p53 by activating caspase 3 in pri-
mary CLL cells. Lin et al. presented combined phase I/II
results of flavopiridol (alvocidib) in 116 relapsed patients
treated at Ohio State, 70% of whom were fludarabine-
refractory [27]. OR in this high-risk population was 47%.
Furthermore, 19/39 del(17p13) patients (49%), 28/47
del(11q22) patients (60%) and 22/52 complex karyotype
patients (42%) responded, demonstrating the activity of
flavopiridol in poor-risk groups with limited therapeutic
options. Forty-one of 85 patients (48%) with bulky lym-
phadenopathy > 5 cm responded. Median PFS in respond-
ers was 10–12 months across all risk groups. Based upon
these promising results, a registration study in 165
relapsed CLL patients is ongoing in the United States and
Europe.
Several monoclonal anti-CD20 antibodies which have
been engineered to improve antibody-dependent cytotox-
icity or complement fixation are under clinical investiga-
tion. Of this new generation of anti-CD20 antibodies,
ofatumumab has generated the most mature clinical data.
Ofatumumab (HuMax-CD20) is a fully humanized, high-
affinity monoclonal antibody whose epitope on the
CD20 molecule of B cells is distinct from that of rituxi-
mab. Ofatumumab has higher affinity for CD20 than
rituximab, activates complement-dependent cytotoxicity
more effectively, and is superior to rituximab in killing B-
cell lines with low CD20 expression. An initial phase I/II
study in 33 patients with relapsed CLL giving weekly ther-
apy for 4 week showed a 50% OR [28]. At the 2008 ASH
meeting, Osterberg et al. presented a pivotal phase II study
of ofatumumab in relapsed patients refractory to both
fludarabine and alemtuzumab (DR, n = 59) or with bulky
lymphadenopathy refractory to fludarabine (BFR, n = 79)
[29]. OR, time to next therapy, and OS were similar for the
DR (51%, 9.0 months, 13.7 months) and BFR groups
(44%, 7.9 months, 15.4 months). Based on these results,
ofatumumab has been submitted for FDA approval.
Investigational Agents
Several exciting novel therapeutic agents are under study,
although a complete description of these drugs is beyond
the scope of this review. ABT-263, a small molecule inhib-
itor of Bcl-2, has shown clinical activity as a single agent
in CLL, and studies of this drug in combination with other
agents are ongoing. Based on the prior results with fla-
vopiridol, several new CDK inhibitors are under clinical
study. The MDACC has studied SNS-032, an inhibitor of
CDK 2, 7 and 9. SCH 727965 is a CDK inhibitor which
appears to have a better therapeutic window than fla-
vopiridol, and this drug is under study in relapsed CLL as
well as non-Hodgkin's lymphoma and multiple mye-
loma. The CD37 small molecule inhibitor (SMIP), Tru-
016, is under investigation in relapsed CLL, and initial
results of this study will be presented at the 2009 ASCO
meeting. Similarly, preclinical results of an ongoing phase
I study of CAL-101, an orally available inhibitor of the
phosphatidylinositol-3-kinase (PI-3-K) delta isoform, will
be presented at the ASCO meeting. Other novel agents are
under preclinical and clinical study, but space precludes a
discussion of these agents in their review.Journal of Hematology & Oncology 2009, 2:29 http://www.jhoonline.org/content/2/1/29
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A Risk Stratified Approach
Fluorescence in situ hybridization (FISH) to determine
cytogenetic abnormalities is now the standard of care in
CLL; any practicing hematologist or oncologist has access
to commercial laboratories which can perform adequate
FISH testing. FISH should be performed before making
treatment decisions in the upfront or relapsed setting, and
it is important to remember that patients will acquire
increasing chromosomal abnormalities in their CLL cells
as their disease becomes more advanced over time. For
previously untreated patients with del(11q22), FC or FCR
should be considered in light of randomized studies
showing marked improvement in CR and PFS with the
addition of cyclophosphamide to fludarabine [3-5].
Unfortunately, there remains no standard of care for pre-
viously untreated patients with del(17p13), and these
patients should be considered for non-myeloablative all-
ogeneic stem cell transplantation after first treatment.
Similarly, patients with del(17p13) are the largest thera-
peutic challenge in the relapsed setting, particularly given
the increasing frequency of del(17p13) in relapsed
patients. Alemtuzumab is active in these patients,
although patients should be observed closely for hemato-
logic and infectious toxicity [25]. Flavopiridol and lenal-
idomide are promising, but neither drug is approved for
CLL [18,27,30]. Sadly, allogeneic stem cell transplanta-
tion remains the only therapy which offers prolonged PFS
in these high-risk del(17p13) patients.
Selecting a Treatment Regimen
Chemoimmunotherapy regimens such as FCR have
achieved OR and CR rates in excess of 90% and 70%,
respectively, and improved PFS in previously untreated
CLL [7]. However, no OS advantage has been demon-
strated for such regimens, due to similar improvements in
treatment of relapsed CLL. Furthermore, patients in the
community are generally older and in poorer medical
condition than patients enrolled in upfront clinical stud-
ies at academic centers. Additionally, the goal of therapy
may be different in older patients with multiple co-mor-
bid medical conditions, in whom palliation of symptoms
may be more important, than in younger patients in excel-
lent health who hope to maximize their likelihood of
long-term survival. Finally, risk stratification by cytoge-
netic features allows hematologists to identify patients,
such as those with del(17p13), who require more aggres-
sive treatment. Thus, there is no "best" initial therapy for
CLL; treatment should be selected for an individual
patient after considering the above points. Chlorambucil
is still a reasonable option in elderly patients with multi-
ple co-morbid illnesses who are poor candidates for
fludarabine or in whom the primary goal is palliation.
PCR is an alternative option for older patients in whom
more aggressive therapy is desired [9]. Younger patients,
particularly those who possess high-risk cytogenetic fea-
tures, should be considered for a chemoimmunotherapy
regimen such as FR or FCR [6,7]. Achievement of MRD
negative marrow should be a therapeutic goal in younger,
poor-risk patients, since eradication of MRD results in
improved survival [12]. Unfortunately, patients with
del(17p13) remain a therapeutic challenge, and non-mye-
loablative allogeneic stem cell transplantation should be
considered for these high-risk patients.
Conclusion
Several important results regarding therapy of CLL in both
the upfront and relapsed settings were presented at the
2008 ASH Annual Meeting. The addition of cyclophos-
phamide or rituximab to purine analogs improves OR, CR
and PFS, but no benefit in overall survival has been docu-
mented to date. Eliminating minimal residual disease
(MRD) improves PFS, and MRD can be assessed from
peripheral blood without the need for additional bone
marrow biopsies. Despite the high CR rates reported with
chemoimmunotherapy regimens in previously untreated
CLL patients in academic centers, these results may not be
reproducible in the community setting, due at least in part
to decreased treatment delivery in the community. Bend-
amustine is active in both the upfront and relapsed set-
ting, although hematologic toxicity requires a lower dose
to be used in relapsed patients. Preliminary results of a
phase II study suggest that the combination of bendamus-
tine and rituximab (BR) may have activity in relapsed
patients with high-risk cytogenetic features, but further
studies are needed to determine whether bendamustine is
an effective therapy for high-risk, relapsed CLL. Lenalido-
mide shows significant activity in high-risk relapsed CLL,
but has limited ability to achieve a CR in the upfront set-
ting and is associated with risks of tumor lysis, tumor flare
and hematologic toxicity. The CDK inhibitor flavopiridol
also demonstrates considerable activity against high-risk
CLL, including bulky lymph node disease, but is associ-
ated with a risk of tumor lysis. The fully humanized anti-
CD20 antibody ofatumumab appears to be superior to
rituximab in relapsed CLL patients with bulky nodal dis-
ease or high-risk cytogenetic features. Ongoing studies of
these agents and multiple other novel therapeutic agents
in various stages of clinical development hold forth the
promise that treatment options for CLL patients will con-
tinue to expand and improve with further clinical studies.
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